- Home
- ROIV vs APTV Comparison
ROIV vs APTV Comparison
Compare ROIV & APTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | APTV |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 16.4B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | ROIV | APTV |
|---|---|---|
| Price | $21.33 | $80.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 19 |
| Target Price | $24.31 | ★ $92.25 |
| AVG Volume (30 Days) | ★ 8.3M | 1.9M |
| Earning Date | 02-09-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | $20,329,000.00 | ★ $20,152,000,000.00 |
| Revenue This Year | N/A | $5.14 |
| Revenue Next Year | $741.42 | $3.88 |
| P/E Ratio | ★ N/A | $60.24 |
| Revenue Growth | N/A | ★ 2.17 |
| 52 Week Low | $8.73 | $47.19 |
| 52 Week High | $23.47 | $88.80 |
Technical Indicators
Market Signals| Indicator | ROIV | APTV |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 59.97 |
| Support Level | $21.36 | $76.00 |
| Resistance Level | $22.21 | $77.05 |
| Average True Range (ATR) | 0.73 | 1.45 |
| MACD | -0.17 | 0.33 |
| Stochastic Oscillator | 19.30 | 93.82 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About APTV Aptiv PLC
Aptiv PLC signal and power solutions segment supplies components and systems that make up a vehicle's electrical system, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The operating segments are grouped on the basis of similar product, market and operating factors: Signal and Power Solutions, which includes complete electrical architecture and component products. advanced Safety and User Experience, which includes vehicle technology and services in advanced safety, user experience, and smart vehicle computing and software, as well as cloud-native software platforms, autonomous driving technologies, and DevOps tools. Eliminations and Other.